There are two types of meningococcal vaccines available in the United States. The older vaccine is a polysaccharide vaccine called MPSV4 and goes by the trade name Menomune. It is recommended for highrisk children two years of age and older. High-risk children include those without a functional spleen or with certain immunodeficiencies.
The second vaccine is a newer polysaccharide vaccine. It is known as MCV4 and goes by the trade name of Menactra. Menactra is at least as effective in preventing meningitis infections as Menomune and possibly lasts longer. The recommendation is to give this vaccine to all children at their elevenor twelve-year-old well-child checkup, with catch-up doses recommended for older teenagers. In addition, high-risk children from ages two to ten years can also receive Menactra instead of Menomune.